Merck faces ongoing claims after Texan ruling on rofecoxib
نویسندگان
چکیده
منابع مشابه
Rofecoxib, Merck, and the FDA.
The new england journal of medicine 2875 correspondence Rofecoxib, Merck, and the FDA to the editor: Merck has been proactive and conscientious in evaluating the cardiovascular profile of rofecoxib (Vioxx); Dr. Topol's remarks to the contrary in his Perspective article (Oct. 21 issue) 1 are false. First, his description of the time line obfus-cates the facts. The Food and Drug Administration (F...
متن کاملFailing the public health--rofecoxib, Merck, and the FDA.
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had taken this medicine and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes. This represents the largest prescription-drug withdrawal in hi...
متن کاملLeprosy in a texan.
A 69-year-old man from Texas with an unremarkable past medical history presented with a 2-year history of a diffuse, spreading annular eruption involving most of his trunk. He noticed progressive numbness of his hands and feet but no other systemic symptoms. He had never traveled outside of the United States. Skin biopsy confirmed a diagnosis of leprosy, and he was initiated on appropriate ther...
متن کاملWorldwide drug withdrawal puts FDA under scrutiny Merck faces 300 lawsuits Karen
Vioxx is a cyclooxygenase (COX)-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by the USA’s Food and Drug Administration (FDA) in May 1999 for the relief of the signs and symptoms of osteoarthritis, the management of acute pain in adults, and the treatment of menstrual symptoms. Vioxx was later also approved for the relief of signs and symptoms of rheumatoid arthrit...
متن کاملMerck Animal Health
Lancaster R.T., Foxcroft, G.R., Boland, M.R, Edwards, S. and Gordon, I., 1985. Fertility of sows treated with exogenous estradiol and/or gonadotropins to control postweaning estrus. Anim. Reprod. Sci., 8:365-373 In the first of two experiments 28 multiparous sows were allocated to one of the following treatments two days after weaning at approximately 35 days postpartum: (1) untreated; (2) i.m....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2005
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.331.7515.471